From Icos: The Son Of Viagra?

If it's true that biotechnology stocks are starting a long bull run, as some analysts believe, Jim McCamant is ahead of the pack. He has been pounding the table for investors to invest in biotechs, a group he says is pregnant with future Genentechs, Chirons, and Amgens.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.